Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Nat Cell Biol ; 1(8): 507-13, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10587647

RESUMEN

Melanoma chondroitin sulphate proteoglycan (MCSP) is a cell-surface antigen that has been implicated in the growth and invasion of melanoma tumours. Although this antigen is expressed early in melanoma progression, its biological function is unknown. MCSP can stimulate the integrin-alpha4 beta1-mediated adhesion and spreading of melanoma cells. Here we show that stimulated MCSP recruits tyrosine-phosphorylated p130 cas, an adaptor protein important in tumour cell motility and invasion. MCSP stimulation also results in a pronounced activation and recruitment of the Rho-family GTPase Cdc42. MCSP-induced spreading of melanoma cells is dependent upon active Cdc42, a Cdc42-associated tyrosine kinase (Ack-1) and tyrosine phosphorylation of p130cas. Furthermore, vectors inhibiting Ack-1 or Cdc42 expression and/or function abrogate MCSP-induced tyrosine phosphorylation and recruitment of p130cas. Our findings indicate that MCSP may modify tumour growth or invasion by a unique signal-transduction pathway that links Cdc42 activation to downstream tyrosine phosphorylation and subsequent cytoskeletal reorganization.


Asunto(s)
Proteoglicanos Tipo Condroitín Sulfato/metabolismo , Melanoma/metabolismo , Melanoma/patología , Fosfoproteínas/metabolismo , Proteínas Tirosina Quinasas/metabolismo , Proteínas , Proteína de Unión al GTP cdc42/metabolismo , Movimiento Celular , Proteína Sustrato Asociada a CrK , Activación Enzimática , Humanos , Integrina alfa4beta1 , Integrinas/metabolismo , Melanoma/genética , Mutación/genética , Invasividad Neoplásica , Fosforilación , Fosfotirosina/metabolismo , Pruebas de Precipitina , Unión Proteica , Proteínas Tirosina Quinasas/genética , Receptores Mensajeros de Linfocitos/metabolismo , Proteína p130 Similar a la del Retinoblastoma , Transducción de Señal , Transfección , Células Tumorales Cultivadas , Proteína de Unión al GTP cdc42/genética
2.
Ophthalmologe ; 117(4): 359-365, 2020 Apr.
Artículo en Alemán | MEDLINE | ID: mdl-31520116

RESUMEN

BACKGROUND: There is no consensus about the best method for pterygium excision. Variable recurrence rates have been reported in the literature depending on the surgical technique. OBJECTIVE: To evaluate the postoperative outcome after pterygium excision depending on the preoperative extent of the pterygium and the surgical method. MATERIAL AND METHODS: A total of 109 patients (72 men, 37 women) who underwent 109 pterygium surgeries were retrospectively analyzed. In 87 cases postoperative data over a 5-year follow-up period were available. Besides recording the preoperative extent of the pterygium the functional outcome was analyzed and recurrence rates of the various techniques by simple excision with primary conjunctival closure (SE), conjunctival autograft (BHT) and amniotic membrane transplantation (AMT) were compared. RESULTS: Overall, recurrence was noted in 21 %. The recurrence rate of SE was 20 %. After BHT fewer recurrences (11 %) were seen than after AMT (39 %). After the intraoperative use of mitomycin C (MMC) more recurrences (31 %) occurred than without the use of MMC (17%). In 45 % of the cases delayed recurrence occurred after the first postoperative year. CONCLUSION: In our opinion the method of SE is not obsolete. Good results can be achieved with SE in pterygia with a small extent. The lowest recurrence rate was seen after BHT; therefore, BHT is the method of choice in general and especially for larger pterygia. The higher recurrence rate after intraoperative use of MMC is probably caused by selection bias. Regular follow-up examinations are required beyond the first postoperative year for timely detection of delayed recurrence.


Asunto(s)
Pterigion , Conjuntiva , Femenino , Estudios de Seguimiento , Humanos , Masculino , Mitomicina , Pterigion/cirugía , Recurrencia , Estudios Retrospectivos , Trasplante Autólogo , Resultado del Tratamiento
4.
Oncogene ; 28(39): 3429-41, 2009 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-19597464

RESUMEN

Complete loss or interstitial deletions of chromosome 5 are the most common karyotypic abnormality in myelodysplastic syndromes (MDSs). Isolated del(5q)/5q- MDS patients have a more favorable prognosis than those with additional karyotypic defects, who tend to develop myeloproliferative neoplasms (MPNs) and acute myeloid leukemia. The frequency of unbalanced chromosome 5 deletions has led to the idea that 5q harbors one or more tumor-suppressor genes that have fundamental roles in the growth control of hematopoietic stem/progenitor cells (HSCs/HPCs). Cytogenetic mapping of commonly deleted regions (CDRs) centered on 5q31 and 5q32 identified candidate tumor-suppressor genes, including the ribosomal subunit RPS14, the transcription factor Egr1/Krox20 and the cytoskeletal remodeling protein, alpha-catenin. Although each acts as a tumor suppressor, alone or in combination, no molecular mechanism accounts for how defects in individual 5q candidates may act as a lesion driving MDS or contributing to malignant progression in MPN. One candidate gene that resides between the conventional del(5q)/5q- MDS-associated CDRs is DIAPH1 (5q31.3). DIAPH1 encodes the mammalian Diaphanous-related formin, mDia1. mDia1 has critical roles in actin remodeling in cell division and in response to adhesive and migratory stimuli. This review examines evidence, with a focus on mouse gene-targeting experiments, that mDia1 acts as a node in a tumor-suppressor network that involves multiple 5q gene products. The network has the potential to sense dynamic changes in actin assembly. At the root of the network is a transcriptional response mechanism mediated by the MADS-box transcription factor, serum response factor (SRF), its actin-binding myocardin family coactivator, MAL, and the SRF-target 5q gene, EGR1, which regulate the expression of PTEN and p53-family tumor-suppressor proteins. We hypothesize that the network provides a homeostatic mechanism balancing HPC/HSC growth control and differentiation decisions in response to microenvironment and other external stimuli.


Asunto(s)
Actinas/metabolismo , Cromosomas Humanos Par 5/genética , Genes Supresores de Tumor , Síndromes Mielodisplásicos/genética , Animales , Humanos , Leucemia Mieloide Aguda/genética , Ratones
5.
J Biol Chem ; 276(34): 31858-62, 2001 Aug 24.
Artículo en Inglés | MEDLINE | ID: mdl-11445557

RESUMEN

Activation of Akt/PKB by growth factors requires multiple phosphorylation events. Phosphorylation of Thr(308) and Ser(473) of Akt by its upstream kinase(s) or autophosphorylation is critical for optimal activation of its kinase activity. Here, we present evidence that tyrosine phosphorylation is required for Akt activation. Epidermal growth factor treatment induces tyrosine phosphorylation of Akt in COS1 and PC3M cells, which is abrogated by PP2, a selective inhibitor for Src family tyrosine kinases. Elevated Akt activity is observed in v-Src transformed NIH3T3 cells, which is accompanied with increased tyrosine phosphorylation of Akt. Akt activity induced by growth factors is significantly reduced in SYF cells lacking Src, Yes, and Fyn, which can be restored by introducing c-Src, but not the kinase-inactive Src, back to these cells. Furthermore, we have identified two tyrosine residues near the activation loop of Akt that are important for its activation. Substitution of these residues with phenylalanine abolishes Akt kinase activity stimulated by growth factors. These two YF mutants fail to block Forkhead transcription factor activity in 293 cells and are unable to prevent apoptosis induced by matrix detachment. Our data suggest that, in addition to phosphorylation of Thr(308) and Ser(473), tyrosine phosphorylation of Akt may be essential for its biological function.


Asunto(s)
Proteínas Serina-Treonina Quinasas , Proteínas Proto-Oncogénicas/metabolismo , Tirosina/metabolismo , Secuencia de Aminoácidos , Animales , Línea Celular , Activación Enzimática , Humanos , Ratones , Datos de Secuencia Molecular , Proteína Oncogénica pp60(v-src)/metabolismo , Fosforilación , Proteínas Proto-Oncogénicas c-akt
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA